Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.
Biomark Med
; 15(11): 851-859, 2021 08.
Article
em En
| MEDLINE
| ID: mdl-33983042
ABSTRACT
Aim:
We intended to survey the prognostic utility of pretreatment neutrophil-to-lymphocyte ratio (NLR) as a novel prognostic index in recurrent glioblastoma multiforme (R-GBMs) treated with bevacizumab plus irinotecan (BEVIRI). Patients &methods:
The present retrospective investigation incorporated the R-GBMs patients who underwent BEVIRI. The pre-BEVIRI NLR was calculated for each patient by utilizing the complete blood count tests obtained on the first day of BEVIRI.Results:
The data of a total of 103 patients were analyzed. The ideal cutoff was identified at 3.04 (area under the curve 60%; sensitivity 60.3%; specificity 60%) for the pre-BEVIRI NLR. Low-NLR group had significantly longer overall survival times than the high-NLR group (15.8 vs 9.3 months; p = 0.015).Conclusion:
NLR might be utilized as a novel biomarker in the prognostic stratification of the R-GBMs treated with BEVIRI.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Glioblastoma
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Biomark Med
Assunto da revista:
BIOQUIMICA
/
MEDICINA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Turquia